IKT vs. SNTI, COEP, SRNE, GENE, ONVO, PMCB, BCDA, SRZN, APTO, and CELZ
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Senti Biosciences (SNTI), Coeptis Therapeutics (COEP), Sorrento Therapeutics (SRNE), Genetic Technologies (GENE), Organovo (ONVO), PharmaCyte Biotech (PMCB), BioCardia (BCDA), Surrozen (SRZN), Aptose Biosciences (APTO), and Creative Medical Technology (CELZ). These companies are all part of the "biological products, except diagnostic" industry.
Inhibikase Therapeutics (NYSE:IKT) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.
3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 20.3% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 12.5% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Inhibikase Therapeutics currently has a consensus target price of $27.00, suggesting a potential upside of 1,418.05%. Senti Biosciences has a consensus target price of $6.00, suggesting a potential upside of 2,035.99%. Given Senti Biosciences' higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Inhibikase Therapeutics.
In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 2 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.67 beat Inhibikase Therapeutics' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.
Inhibikase Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Inhibikase Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500.
Senti Biosciences has a net margin of -2,692.82% compared to Inhibikase Therapeutics' net margin of -5,886.15%. Senti Biosciences' return on equity of -74.59% beat Inhibikase Therapeutics' return on equity.
Inhibikase Therapeutics received 2 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 83.33% of users gave Inhibikase Therapeutics an outperform vote while only 33.33% of users gave Senti Biosciences an outperform vote.
Summary
Senti Biosciences beats Inhibikase Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
